IBN (InvestorBrandNetwork) Coverage Initiated for BiondVax Pharmaceuticals Ltd. LOS ANGELES, Dec. 06, 2022 (GLOBE NEWSWIRE) -- via InvestorWire – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), a biopharmaceutical company focused on developing, manufacturing and commercializing...

BiondVax reports successful results in preclinical in vivo study of its innovative inhaled COVID-19 NanoAb therapy Hamsters infected with SARS-COV-2 and then treated with inhaled anti-COVID-19 NanoAbs demonstrated significantly less severe illness and faster recovery in comparison to infected hamsters treated with...